Scientific Timetable & Daily Schedule
Full two-day scientific curriculum across bioconjugation chemistries, targeted alpha radiopharmaceuticals, theranostic imaging, and GMP supply chain engineering. All sessions include dedicated collegiate discussion periods and CME compliance logging.
Wednesday, April 21, 2027
Delegate Accreditation Desk & Badge Distribution
Verification of institutional credentials, distribution of conference portfolios, and speaker slide uploads.
Secretariat Welcome & Opening Plenary Lecture
The Convergence Paradigm: Engineering the next generation of bioconjugates and radioligands to overcome tumor heterogeneity and solid tumor resistance.
Track 01: Novel Bioconjugation Chemistries & Cleavable Linker Design
Proffered podium defenses covering site-specific enzymatic conjugation, hydrophilic PEG shields, and Cathepsin B-cleavable lysosomal release kinetics. Structured Q&A following each defense.
Morning Discussion Break & Moderated Poster Walk (Session 1)
Poster author defense sessions across Track 01 & Track 02 submissions. Refreshments served in the exhibition concourse.
Track 02: Next-Gen Warheads, Payloads & Bispecific Conjugates
Clinical evaluation of Topoisomerase I payloads (DXd/SN-38 derivatives), immune-stimulating antibody conjugates (ISACs), and Degrader-Antibody Conjugates (DACs).
Colloquium Luncheon & Pre-Scheduled Bilateral Matchmaking
Structured delegate dining alongside pre-arranged 1-on-1 buyer meetings between biotech sponsors, CDMOs, and clinical program directors in Saloon Alpha & Beta.
Translational Plenary: Overcoming ADC Clinical Toxicity & Resistance
Invited institutional panel examining interstitial lung disease (ILD), ocular toxicities, and payload extrusion mechanisms across active multicenter clinical trials.
Afternoon Networking & Matchmaking Exchange
Technical demonstration stations and scheduled commercial introductions.
Late-Breaking Clinical Trial Proffered Papers
Rapid-fire 10-minute defenses of Phase I/II preliminary trial datasets, biomarker stratification cohorts, and pharmacokinetics in patient populations.
Welcome Networking Reception & Parisian Faculty Aperitif
Informal faculty evening reception. Hosted networking for authors, hospital PIs, and enterprise delegates.
Thursday, April 22, 2027
Day 2 Plenary: Targeted Alpha Therapies & High-LET Radiobiology
Clinical advances and recoil daughter containment strategies in Actinium-225 (225Ac) and Lead-212 (212Pb) therapeutic translation.
Track 03: Targeted Alpha Therapies (TAT) & Macrocyclic Radioligands
Chelator chemistry (Macropa, DOTA variants), radiolabeling stability at physiological pH, and pre-targeting strategies for clearing non-bound radioisotopes.
Discussion Break & Moderated Poster Walk (Session 2)
Poster author defense sessions across Track 03, Track 04 & Track 05 submissions. Refreshments served in the concourse.
Track 04: Clinical Theranostics, 3D Dosimetry & PET/SPECT Imaging
Quantitative voxel-based dosimetry, Gallium-68/Lutetium-177 treatment pairs, and strategies to prevent nephrotoxicity in mCRPC and neuroendocrine tumors.
Colloquium Luncheon & Final Matchmaking Session
Final round of 1-on-1 pre-qualified buyer briefings in Saloon Alpha & Beta. Concourse networking for general delegates.
Track 05: Radioisotope Supply Chain, GMP Production & Safety
Accelerating Actinium-225 cyclotron and reactor supply, hot-cell microfluidics, radiation shielding, and cross-border cold-chain logistics.
Afternoon Coffee & Secretariat Appraisal Desk
Delegates verify their 14.5 Educational Contact Hours record and submit session evaluation sheets.
Closing Plenary: 2027–2030 Clinical Roadmap & Young Investigator Awards
Summation of clinical trial benchmarks, best poster awards presentation, and formal adoption of the Paris Theranostics Working Consensus.
Official Adjournment of ADC-RadCon 2027
Issuance of digital certificates of participation and post-colloquium compendium access.